Quantcast

Latest Thiophenes Stories

2011-12-06 14:00:00

GENE-MATRIX study to determine optimal antiplatelet therapy for 4,000 cardiac stent patients Ottawa, Ontario (PRWEB) December 06, 2011 Spartan Bioscience today announced the start of GENE-MATRIXâ”the largest clinical trial to date of point-of-care DNA testing in medicine. The randomized prospective trial will enroll 4,000 patients over 2 years at up to 40 hospitals in Italy. The Spartan RX CYP2C19 point-of-care DNA testing system will be used to test heart attack patients...

2011-11-28 14:00:00

Takeda Pharmaceuticals North America, Inc., (Takeda) announced the DEXILANT (dexlansoprazole) product labeling now includes information from a study in healthy subjects demonstrating that DEXILANT had no clinically important effect on exposure to the active metabolite of clopidogrel or clopidogrel-induced platelet inhibition. No dose adjustment of clopidogrel is necessary when administered with an approved dose of DEXILANT. DEXILANT is a proton pump inhibitor (PPI) indicated for the treatment...

2011-11-16 09:32:58

Among patients with stable cardiovascular disease who have a genetic variation that diminishes the response to the antiplatelet drug clopidogrel, tripling the standard daily dosage of this medication resulted in improved platelet reactivity, according to a study appearing in JAMA. The study is being released early online to coincide with its presentation at the American Heart Association Scientific Sessions. "Variants in the CYP2C19 gene influence the pharmacologic and clinical response to...

2011-11-14 22:28:32

BIDMC researcher says improvement in survival rates best 'since introduction of aspirin' An oral anti-clotting drug, when added to standard medical treatment for acute coronary syndrome, lowered the risk of death, heart attack or stroke an average of 16 percent, according to research presented at the American Heart Association's Scientific Sessions. The results were also published online by the New England Journal of Medicine. The drug, rivaroxaban, proved effective in preventing the...

2011-11-09 20:30:00

Positive RAPID GENE results presented at the Transcatheter Cardiovascular Therapeutics conference Ottawa, Ontario (PRWEB) November 09, 2011 Spartan Bioscience today announced data from the RAPID GENE study showing that point-of-care DNA testing successfully identified patients carrying the CYP2C19*2 gene at the time of cardiac catheterization. Cardiologists were then able to prescribe antiplatelet therapy according to the patientâs genotype. This personalized medicine approach...

2011-11-09 22:42:38

Tailored therapy for anti-platelet drugs using a novel point-of-care genetic test provides improved response to medications compared to current standard of care A clinical trial of patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) and stable angina showed that a strategy of rapid genotyping followed by selective administration of prasugrel to carriers of a common genetic variant (CYP2C19*2) resulted in a decreased rate of high on-treatment...

2011-11-09 22:33:32

Patients with acute coronary syndrome and/or diabetes who show poor response to dual antiplatelet therapy as measured by platelet function testing are at greater risk of stent thrombosis after percutaneous coronary intervention with drug-eluting stents The relationship of platelet responsiveness to antiplatelet medications; and, the correlation of poor response, and overall platelet aggregation while on dual antiplatelet therapy to the risk of drug-eluting stent thrombosis after 30 days...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.